🇪🇺 Teriparatide (Forteo) in European Union

EMA authorised Teriparatide (Forteo) on 24 April 2017

Marketing authorisation

EMA — authorised 24 April 2017

  • Application: EMEA/H/C/003861
  • Marketing authorisation holder: Takeda Pharmaceuticals International AG Ireland Branch
  • Local brand name: Natpar
  • Indication: Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
  • Pathway: conditional, orphan
  • Status: approved

Read official source →

Frequently asked questions

Is Teriparatide (Forteo) approved in European Union?

Yes. EMA authorised it on 24 April 2017.

Who is the marketing authorisation holder for Teriparatide (Forteo) in European Union?

Takeda Pharmaceuticals International AG Ireland Branch holds the EU marketing authorisation.